Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyntra Bio (KYNB) Long-Term Investments (2016 - 2025)

Historic Long-Term Investments for Kyntra Bio (KYNB) over the last 12 years, with Q3 2025 value amounting to $3.0 million.

  • Kyntra Bio's Long-Term Investments fell 4772.65% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year decrease of 4772.65%. This contributed to the annual value of $5.3 million for FY2023, which is 452.48% up from last year.
  • As of Q3 2025, Kyntra Bio's Long-Term Investments stood at $3.0 million, which was down 4772.65% from $5.8 million recorded in Q3 2024.
  • Kyntra Bio's Long-Term Investments' 5-year high stood at $105.8 million during Q2 2021, with a 5-year trough of $3.0 million in Q3 2025.
  • Over the past 5 years, Kyntra Bio's median Long-Term Investments value was $5.2 million (recorded in 2022), while the average stood at $16.8 million.
  • In the last 5 years, Kyntra Bio's Long-Term Investments soared by 4608253.28% in 2021 and then plummeted by 9575.07% in 2022.
  • Quarter analysis of 5 years shows Kyntra Bio's Long-Term Investments stood at $3.8 million in 2021, then skyrocketed by 32.31% to $5.1 million in 2022, then rose by 4.52% to $5.3 million in 2023, then grew by 9.75% to $5.8 million in 2024, then tumbled by 47.73% to $3.0 million in 2025.
  • Its Long-Term Investments stands at $3.0 million for Q3 2025, versus $5.8 million for Q3 2024 and $6.9 million for Q2 2024.